CNDP1 and Parkinson disease: Although CN1 is expressed by the human olfactory epithelium14, the nasal cavity is not typically considered a site of high carnosinase activity, such that intranasal administration of carnosine has been employed in a preclinical model of Parkinson disease as a means to avoid degradation by carnosinase15.